1 min read
Add as a preferred source on GoogleAstraZeneca Reports Third-Quarter Core Earnings of $2.79 Per Share
Core earnings per share rose 19% at constant exchange rates. Oncology revenue increased 16% in the first nine months of 2026.
AstraZeneca PLC reported third-quarter core earnings of $2.79 per share, up 19% at constant exchange rates. The company’s oncology revenue rose 16% during the first nine months of 2026.
The oncology growth figure covers the nine-month period, while the earnings figure is for the third quarter.
The results follow TokenPost’s preview of AstraZeneca’s scheduled earnings release.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.